Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

Inclusion Criteria:

• Participant diagnosed with DME in the study eye

• Study eye has received at least 3 and no more than 9 anti-VEGF injections in the 12months prior to DEX-I initiation

• Study eye newly prescribed DEX-I. The prescribing decision lies with the physicianand reflects their standard practice

• Participant showing a suboptimal response to anti-VEGF at Baseline in the study eye

Exclusion Criteria:

• Any concomitant ocular or neurologic condition in the study eye that could causemacular edema or affect vision (except cataract)

• History of ocular surgery within 60 days of Baseline in the study eye

• History of Pan-Retinal Photocoagulation (PRP) or sectorial photocoagulation in thestudy eye in the 3 months prior to Baseline

• Significant media opacities in the study eye limiting Optical Coherence Tomography (OCT) quality

• Uncontrolled Ocular Hypertension (OHT) or advanced glaucoma in the study eye

• Active ocular inflammation in either eye

• Study eyes that are aphakic with Posterior Capsule Rent (PCR), Anterior ChamberIntraocular Lens (ACIOL), iris or scleral-fixed Intraocular Lens (IOL) or history ofcomplicated cataract surgery with PCR

• Prior use of intravitreal corticosteroids in the study eye

• Patients with contraindications to DEX-I